(Q73500412)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

R Waśko

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J Sawicka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Kotwicka

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J Sowiński

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

12-18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10698045%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf03343669

4 November 2019

exact match

0 references

cites work

Growth-hormone and prolactin excess.

1 reference

12 December 2020

CV 205-502 treatment in therapy-resistant acromegalic patients

1 reference

12 December 2020

Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995)

1 reference

12 December 2020

Classification and nomenclature of somatostatin receptors

1 reference

12 December 2020

Depot-bromocriptine treatment for prolactinomas and acromegaly

1 reference

12 December 2020

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

1 reference

12 December 2020

Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

1 reference

12 December 2020

Molecular pharmacology of somatostatin receptors.

1 reference

12 December 2020

Effect of octreotide pretreatment on surgical outcome in acromegaly

1 reference

12 December 2020

Somatostatin analogs in the treatment of acromegaly.

1 reference

12 December 2020

Acromegaly--the place of the neurosurgeon

1 reference

12 December 2020

In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide

1 reference

12 December 2020

Cabergoline treatment of acromegaly: a preliminary dose finding study

1 reference

12 December 2020

Medical therapy with somatostatin analogues for acromegaly

1 reference

12 December 2020

Clinical results of long-term slow-release lanreotide treatment of acromegaly

1 reference

12 December 2020

Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men

1 reference

12 December 2020

Cabergoline in the treatment of acromegaly: a study in 64 patients.

1 reference

12 December 2020

Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients

1 reference

12 December 2020

Medical management of acromegaly--what and when?

1 reference

12 December 2020

Octreotide treatment of acromegaly. A randomized, multicenter study

1 reference

12 December 2020

Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?

1 reference

12 December 2020

Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly

1 reference

12 December 2020

Octreotide as primary therapy for acromegaly.

1 reference

12 December 2020

Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas

1 reference

12 December 2020

[Efficacy of delayed-release lanreotide in the medical therapy of acromegaly]

1 reference

12 December 2020

Presurgical octreotide treatment in acromegaly

1 reference

12 December 2020

Prediction of efficacy of octreotide therapy in patients with acromegaly.

1 reference

12 December 2020

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

1 reference

12 December 2020

Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery

1 reference

12 December 2020

Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients

1 reference

12 December 2020